These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25011422)

  • 21. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
    Kira J; Itoyama Y; Kikuchi S; Hao Q; Kurosawa T; Nagato K; Tsumiyama I; von Rosenstiel P; Zhang-Auberson L; Saida T
    BMC Neurol; 2014 Jan; 14():21. PubMed ID: 24475777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
    La Mantia L; Prone V; Marazzi MR; Erminio C; Protti A
    Neurol Sci; 2014 Sep; 35(9):1485-6. PubMed ID: 24756193
    [No Abstract]   [Full Text] [Related]  

  • 23. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V; Saiva L; O'Kelly S; Keane D
    Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
    [No Abstract]   [Full Text] [Related]  

  • 24. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
    Thomas K; Schrötter H; Halank M; Ziemssen T
    BMC Neurol; 2014 Jun; 14():126. PubMed ID: 24906818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
    Havla JB; Pellkofer HL; Meinl I; Gerdes LA; Hohlfeld R; Kümpfel T
    Arch Neurol; 2012 Feb; 69(2):262-4. PubMed ID: 22332194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report.
    Maciejek Z; Wójcik-Drączkowska H; Wawrzyniak S; Niezgodzińska-Maciejek A
    Neurol Neurochir Pol; 2013; 47(2):145-51. PubMed ID: 23650003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
    Tichá V; Počíková Z; Vytlačil J; Štěpánová R
    BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.
    Muris AH; Rolf L; Damoiseaux J; Koeman E; Hupperts R
    BMC Neurol; 2014 Aug; 14():164. PubMed ID: 25138918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F; Kowarik MC; Albrecht H; Krause M; Haslinger B; Zimmer C; Berthele A; Hemmer B
    Neurology; 2012 Mar; 78(12):928-30. PubMed ID: 22402856
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
    Berger B; Baumgartner A; Rauer S; Mader I; Luetzen N; Farenkopf U; Stich O
    J Neuroimmunol; 2015 May; 282():118-22. PubMed ID: 25903738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of fingolimod in clinical practice.
    Thomas K; Ziemssen T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S60-4. PubMed ID: 24321158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
    Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
    Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Fazekas F; Berger T; Fabjan TH; Ledinek AH; Jakab G; Komoly S; Kraus J; Kurča E; Kyriakides T; Lisý L; Milanov I; Panayiotou P; Jazbec SS; Taláb R; Traykov L; Turčáni P; Vass K; Vella N; Havrdová E
    Wien Med Wochenschr; 2012 Aug; 162(15-16):354-66. PubMed ID: 22895849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
    Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla AA; Karkare SU; McGuiness CB; Korn JR
    PLoS One; 2014; 9(2):e88472. PubMed ID: 24516663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.